Suven Life Sciences Ltd has secured one product patent each from Eurasia, Japan and one from Mexico for its New Chemical Entities (NCEs).
The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company and were being developed as therapeutic agents.
“`They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia,’’ Suven said in a release issued here on Tuesday.
With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico. Business Line
Achieves significant advancement in Cancer Treatment to Enhance Quality of Life As per the National…
-An 11-year-old boy from Yemen and a 34-year-old man from Bengaluru, both suffered from end-stage…
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…